Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure–Related Clinical Trials With a Treatment Interruption

• Published in: The Journal of infectious diseases Vol. 220; no. Supplement_1; pp. S16 - S18
• Main Author: Lelièvre, Jean-Daniel
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 02.07.2019
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Antiretroviral drugs; Clinical trials; Clinical Trials as Topic; Condoms; Disease prevention; Disease transmission; HIV; HIV Infections - prevention & control; HIV Infections - transmission; Human immunodeficiency virus; Humans; Male; Pre-Exposure Prophylaxis; Prophylaxis; Risk Factors; Sexual Partners; Supplement; SUPPLEMENT ARTICLES; Tenofovir - administration & dosage; Vaccines - administration & dosage; Withholding Treatment; PrEP; HIV; analytical treatment interruption; HIV transmission
• ISSN: 0022-1899; 1537-6613; 1537-6613
• DOI: 10.1093/infdis/jiz036

Analytical treatment interruption performed during human immunodeficiency virus (HIV) cure–related clinical trials exposes sex partners of participants in these trials to a risk of HIV transmission. Preexposure prophylaxis (PrEP), which emerged in recent years as a key strategy for preventing HIV transmission, is often considered a useful tool to prevent this risk. This article supports offering PrEP to participants’ sex partners in stable relationships in these trials but also notes limitations that must be addressed. It concludes that PrEP cannot on its own eliminate the risk of secondary transmission in this context.